TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03241069

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reference position
Description: patient is put in a 30 degree supine position during 5 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reference position
Description: patient is put in a 30 degree supine position during 5 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reference position
Description: patient is put in a 30 degree supine position during 5 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reference position
Description: patient is put in a 30 degree supine position during 5 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sitting position
Description: patient is put to a 90 degree sitting position during 1 to 2 minutes then the CO is measured

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sitting position
Description: patient is put to a 90 degree sitting position during 1 to 2 minutes then the CO is measured

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Valsalva maneuver
Description: patients are asked to perform the Valsalva maneuver by executing a forced blow into a manometer for 30 seconds and the CO is calculated during this test.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Valsalva maneuver
Description: patients are asked to perform the Valsalva maneuver by executing a forced blow into a manometer for 30 seconds and the CO is calculated during this test.
Study: NCT00763204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2728 Cream, 1%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2728 Cream, 0.3%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AN2728 Cream Vehicle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betnesol®-V Creme, 0.1%
Study: NCT03854591

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT04237207

Intervention type: DEVICE
Group type: OTHER
Intervention: Naída Cochlear Implant Q90 sound processor (Naida CI Q90) & software
Description: Control cochlear implant sound processor

Intervention type: DEVICE
Group type: OTHER
Intervention: Naída Cochlear Implant Q90 sound processor (Naida CI Q90) & software
Description: Control cochlear implant sound processor

Intervention type: DEVICE
Group type: OTHER
Intervention: 301-M062 sound processor & software
Description: New cochlear implant sound processor
Study: NCT03241069

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: a passive leg rising maneuver
Description: we make a passive leg rising and we measure the cardiac output by BIOPAC system (45 degree passive leg rising was done for 1 to 2 minutes and CO was measured during the maneuver.)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: a passive leg rising maneuver
Description: we make a passive leg rising and we measure the cardiac output by BIOPAC system (45 degree passive leg rising was done for 1 to 2 minutes and CO was measured during the maneuver.)
Study: NCT01232218

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard education/exercises for hemiplegic shoulder pain
Description: Each participant will receive standard education for safe positioning and movement of the painful hemiplegic shoulder. Participants will also be provided with standard stretching and strengthening exercises by and experienced Occupational Therapist who will grade the level of exercise to suit their needs. Intervention will take place 3x/week for 1 hour.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Three dimensional Scapular-Humeral Mobilizations
Description: Each participant will receive standard education for safe positioning and movement of the painful hemiplegic shoulder. Participants will also be provided with stretching and strengthening exercises by and experienced Occupational Therapist who will grade the level of exercise to suit their needs. Intervention will take place 3x/week for 1 hour. Participants in this group will receive an additional scapular humeral mobilization while simultaneously performing the standard stretching/strengthening exercise protocol.
Study: NCT03186885

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Frio In-Person Family-focused Intervention
Description: Participants learn about energy balance behaviors, skills to support health behavior change, managing personal wellness, and parenting strategies. Sessions use interactive learning strategies to elicit knowledge and experience of participating families to encourage families to learn from each other. YMCA staff members lead a 50-minute group exercise session after each health education session to help participants meet their commitment of engaging in PA at least 3 times/week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Frio Remote Technology Family-focused Intervention
Description: Tablet computers will be used as the platform to deliver the health education content for the FI-RT. Each session will present the class content and guide the participants to complete class activities. Videos of health education and class activities (e.g., cooking demonstrations, exercise demonstrations) will be embedded in the lesson. Interactive assessment questions with feedback will be presented throughout the session to check for understanding of the content. Viewing time and responses to the assessment questions will be recorded to evaluate progress and comprehension. Participants will view the health education sessions at home as a family and discuss the content as prompted by lesson instructions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants receive standard of care
Study: NCT02962947

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: 80 mgR propranolol once daily
Study: NCT04237207

Intervention type: DEVICE
Group type: OTHER
Intervention: 301-M062 sound processor & software
Description: New cochlear implant sound processor
Study: NCT02962947

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo once daily
Study: NCT00405327

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor lysate-pulsed dendritic cell (DC) vaccine
Description: Tumor lysate-pulsed dendritic cell vaccine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation (HSCT)
Description: Hematopoietic stem cell transplantation (HSCT)
Study: NCT02542371

Intervention type: OTHER
Intervention: Arterial Imaging
Study: NCT03927495

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: palliative radiotherapy
Description: 3D conformal radiation therapy will be administered for esophageal lesion or nearby lymph node. Stereotactic body radiation will be administered for metastatic lesion.
Study: NCT01681797

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluorescence angiography (Fluobeam™ imaging system developed by Fluoptics company)
Description: Fluorescence angiography after intravenous injection of Infracyanine® (indocyanine green)
Study: NCT01325623

Intervention type: DEVICE
Group type: OTHER
Intervention: Model 106 VNS Therapy System
Description: The VNS Therapy System is an adjunctive therapy for the treatment of epilepsy. VNS Therapy is available as a scheduled stimulation, this is cyclic stimulation between programmable On- and Off- times (e.g., a 30-second burst every 5 minutes). VNS Therapy is also available as on-demand stimulation, that is, when a magnet is introduced briefly over the implanted device (Magnet Mode). The AspireSR VNS Therapy System includes a new feature, Automatic Magnet Mode or AutoStim. In addition to Normal Mode and Magnet Mode, AspireSR uses a Seizure Detection Algorithm to identify a potential seizure onset based on associated heart rate increases known as ictal tachycardia. The purpose is to deliver stimulation at or near the onset of a seizure.
Study: NCT04465162

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT01539642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil NanoTab PCA System/15 mcg
Description: 15 mcg Sufentanil NanoTab dosed sublingually every 20 minutes as needed for pain for up to 48 hours. Patient may elect to remain in study for up to 72 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Sufentanil NanoTab PCA System
Description: Placebo NanoTab dosed sublingually every 20 minutes as needed for pain for up to 48 hours. Patient may elect to remain in study for up to 72 hours.
Study: NCT03927495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN046
Description: Cisplatin+paclitaxel will be administered once every three weeks for four cycles. After completion of radiotherapy, KN046 will be administered once every two weeks until progressive disease, unacceptable toxicity or up to 2 years.
Study: NCT04162587

Intervention type: OTHER
Intervention: Carotid duplex+/- MRA neck
Description: Carotid duplex and or MRA neck

Intervention type: OTHER
Intervention: Carotid duplex+/- MRA neck
Description: Carotid duplex and or MRA neck

Intervention type: OTHER
Intervention: Carotid duplex+/- MRA neck
Description: Carotid duplex and or MRA neck

Intervention type: OTHER
Intervention: Carotid duplex+/- MRA neck
Description: Carotid duplex and or MRA neck

Intervention type: OTHER
Intervention: brain MRA+/-CT angio on carotid and brain
Description: brain MRA and or CT angiography on carotid and brain

Intervention type: OTHER
Intervention: brain MRA+/-CT angio on carotid and brain
Description: brain MRA and or CT angiography on carotid and brain

Intervention type: OTHER
Intervention: brain MRA+/-CT angio on carotid and brain
Description: brain MRA and or CT angiography on carotid and brain

Intervention type: OTHER
Intervention: brain MRA+/-CT angio on carotid and brain
Description: brain MRA and or CT angiography on carotid and brain

Intervention type: OTHER
Intervention: MRI brain
Description: MRI brain with diffusion to detect asymptomatic stroke

Intervention type: OTHER
Intervention: MRI brain
Description: MRI brain with diffusion to detect asymptomatic stroke

Intervention type: OTHER
Intervention: MRI brain
Description: MRI brain with diffusion to detect asymptomatic stroke

Intervention type: OTHER
Intervention: MRI brain
Description: MRI brain with diffusion to detect asymptomatic stroke

Intervention type: OTHER
Intervention: DSA (digital subtraction angiography)
Description: DSA (digital subtraction angiography) in some cases to confirm diagnosis.

Intervention type: OTHER
Intervention: DSA (digital subtraction angiography)
Description: DSA (digital subtraction angiography) in some cases to confirm diagnosis.

Intervention type: OTHER
Intervention: DSA (digital subtraction angiography)
Description: DSA (digital subtraction angiography) in some cases to confirm diagnosis.
Study: NCT02972515

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: See Me Smoke-Free
Description: See Me Smoke-Free is a multi-behavioral mobile application focusing on increasing smoking cessation, healthy eating, and moderate to intense physical activity. The app tracks the participant's quit date, and eating/physical activity goals. Participants have access to guided imagery audio files that they are instructed to listen to every day for at least 30 days. Participants can earn awards for meeting the study goals.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart phone
Description: See Me Smoke-Free mHealth app delivered via a smart phone
Study: NCT03609333

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multimodal Neuromonitoring
Description: Application of multimodal neuromonitoring
Study: NCT02077881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Nab-Paclitaxel 125 mg/m\^2 given intravenously over 30-40 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 given intravenously over 30 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indoximod
Description: Indoximod will be administered in escalating doses. Initial dosing will be 600 mg BID by mouth with escalation planned to 1200 mg BID by mouth~Indoximod in the form of 200 mg capsules will be given (3, 5, and 6 capsules depending on the escalated dose). Indoximod should be taken with water by mouth one hour before breakfast and one hour prior to dinner. The medication should be taken twice daily for 28 days each cycle. Patients will continue until they experience disease progression or toxicity.
Study: NCT03933267

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical sensorimotor control training exercises
Description: Cervical sensory motor training exercises consisting of cervical position sense and cervical movement sense exercises with 3 levels of difficulty and 5 repetitions \* 3 sets for each exercise will be given. Some exercises are:~Head relocation with laser feedback:~head relocation to neutral and predetermined position with eyes opened (in horizontal / vertical direction) (5 reps x 3 sets) Head relocation to neutral, predetermined and to specific targets with eyes opened (in diagonal directions) (5 reps x 3 sets) Head relocation to neutral and predetermined position with eyes closed (in all directions)(5 reps x 3 sets) In addition to it conventional physical therapy protocol consisting of Generalized stretching and cervical strengthening exercises along with joint mobility.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Exercises
Description: conventional physical therapy protocol consisting of Generalized stretching and cervical strengthening exercises along with joint mobility exercises will be given to patients.
Study: NCT04325516

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily activities
Description: Participants will perform four tasks in a randomized order:~* sit to stand~* dorsi flexion of the foot~* knee extension~* hip extension

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily activities
Description: Participants will perform four tasks in a randomized order:~* sit to stand~* dorsi flexion of the foot~* knee extension~* hip extension
Study: NCT00708682

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine
Study: NCT00344045

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: IV Solution, Intravenous, 100 mL (10 mg/mL), 4 times at 6-hour intervals, 24 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV Solution, Intravenous, 100 mL (0 mg/mL), 4 times at 6-hour intervals, 24 hours
Study: NCT00133679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil
Description: Sildenafil 0.5 mg/kg every 6 hours orally x 45 d
Study: NCT04388852

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valemetostat
Description: Given PO
Study: NCT06104150

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervallic submaximal exercise test
Description: Intervallic submáximal exercise test on a cycle ergometer: 5 min warm-up at 80% of First Lactate Threshold (LT1), and subsequent sets of 1.5 min at 20% above the Second Lactate Threshold (LT2) alternated with recoveries of 5 min at 80% of LT1, ending with a 20 min recovery at 80% of LT1.
Study: NCT00608543

Intervention type: DRUG
Group type: OTHER
Intervention: Aripiprazole
Description: varied dose (5, 10, 15 mg qd) for 6 wks
Study: NCT03137030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRT7014 - Abuse Deterrend Tablet
Description: Single oral dose in one of the four cross-over trial periods and in the standard cross-over trial periods.
Study: NCT00133679

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo suspension (equal volume to experimental drug) x 45 days
Study: NCT00859040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOM230C
Description: Injection in the buttocks every 28 days
Study: NCT03092414

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: WLE and then LCI
Description: The gastric mucosa was evaluated with WLE and then LCI by two different endoscopists.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LCI and then WLE
Description: The gastric mucosa was evaluated with LCI and then WLE by two different endoscopists.
Study: NCT03514355

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: 8 weekly 2.5 h sessions plus one day of practice
Study: NCT01418235

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-C + gp140/MF59
Description: SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid, with placebo in left deltoid, at Month 0; SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid at Month 1; Novartis subtype C gp140 admixed with Novartis MF59 adjuvant administered as 0.5 ml intramuscularly in left deltoid, with placebo in right deltoid, at Months 3, 6.~Placebo comparator: Placebo administered at Months 0, 1, 3, 6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-C + gp140/MF59
Description: SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid, with Novartis subtype C gp140 admixed with Novartis MF59 adjuvant administered as 0.5 ml intramuscularly in left deltoid, at Months 0, 3; placebo in right deltoid at Month 1; placebo in each deltoid at Month 6~Placebo comparator: Placebo administered at Months 0, 1, 3, 6
Study: NCT03137030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRT7014 - Abuse Deterrend Tablet
Description: Single oral dose in one of the four cross-over trial periods and in the standard cross-over trial periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRT7014 - Abuse Deterrend Tablet
Description: Single oral dose in one of the four cross-over trial periods and in the standard cross-over trial periods.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norco 5Mg-325Mg Tablet
Description: Single oral dose in one of the four cross-over trial periods and in the standard cross-over trial periods.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norco 5Mg-325Mg Tablet
Description: Single oral dose in one of the four cross-over trial periods and in the standard cross-over trial periods.
Study: NCT01418235

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA-C2 + MVA-C
Description: SAAVI DNA-C2 administered as 1 ml intramuscularly in right deltoid, with placebo in left deltoid, at Month 0; SAAVI DNA-C2 administered as 1 ml intramuscularly in right deltoid at Month 1; SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid, with placebo in left deltoid, at Months 3, 6~Placebo comparator: Placebo administered at Months 0, 1, 3, 6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA-C2 + MVA-C + gp140/MF59
Description: SAAVI DNA-C2 administered as 1 ml intramuscularly in right deltoid, with placebo in left deltoid, at Month 0; SAAVI DNA-C2 administered as 1 ml intramuscularly in right deltoid at Month 1; SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid at Months 3, 6; Novartis subtype C gp140 admixed with Novartis MF59 adjuvant administered as 0.5 ml intramuscularly in left deltoid, with placebo in right deltoid, at Months 3, 6~Placebo comparator: Placebo administered at Months 0, 1, 3, 6
Study: NCT01085890

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: The intervention consisted of 2 group seminars with information on hypertension and related lifestyle factors and 2 follow-up visits in which blood pressure was measured and motivational interviewing took place. The motivational interviewing focused on lifestyle factors, including physical activity, stress, tobacco use, alcohol habits, and diet.
Study: NCT03137030

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norco 5Mg-325Mg Tablet
Description: Single oral dose in one of the four cross-over trial periods and in the standard cross-over trial periods.
Study: NCT01384071

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unstable shoes (MBT)
Description: Wearing unstable (MBT) shoes during 6 weeks
Study: NCT04011449

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic RC+S DBS system
Description: Implantation of the Medtronic RC+S Deep Brain Stimulation (DBS) system
Study: NCT00409942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torasemide Prolonged Release
Description: Torasemide Prolonged release 10mg/day up to 40mg/day, treatment duration:8 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: Furosemide 40mg/day up to 160mg/day, Treatment duration:8 months
Study: NCT04193579

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Language Treatment
Description: Recording of a mother's voice reading a children's storybook.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control Treatment
Description: Standard of Care
Study: NCT02506205

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lee Silverman Voice Treatment (SVLT) LOUD
Study: NCT02382822

Intervention type: OTHER
Intervention: No intervention.

Intervention type: OTHER
Intervention: No intervention.
Study: NCT01384071

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham intervention (Adidas shoes)
Description: Normal stable shoes (Adidas Bigroar2)
Study: NCT04406285

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard protocol Leukemia
Description: * Bicycle ergometer endurance training for 5 minutes, with resistance individually adjusted based on the patient´s feedback (from 70% of maximum heart rate);~* Resistance exercises for muscle groups: hip flexors, knee extensors and ankle plantar flexors (10 repetitions, 1 sets);~* Resistance training for arms, using 0,5 kg or 1,0 kg dumbbels (10 repetitions, 1 sets).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Periodic Resistance Training Program Leukemia
Description: * Submaximal Ergometer tests with incremental load (from 85% of maximum heart rate or maximum effort related);~* 30-Second Chair Stand;~* Hand Grip Strength and submaximal arm effort using 0,5 kg or 1,0 kg dumbbels.
Study: NCT03155893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMV 150 mg
Description: Participants will receive SMV 150 mg (2\*75 mg capsules) orally once daily administered on Days 2 to 16 in Treatment C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-335 1200 mg
Description: Participants will receive a single oral dose of AL-335 1200 mg (3\*400 mg tablets) administered on Day 15 in Treatment C.
Study: NCT04315779

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Salpingectomy
Description: Patients will undergo removal of the affected tube

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Salpingectomy
Description: Patients will undergo removal of the affected tube